Mogroside III
Based on 1 Customer Validation
Mogroside III is a triterpenoid glycoside. Mogroside III exhibits maltase inhibitory effect with an IC50 value of 1.6 mM. Mogroside III enhances oocyte developmental potential by promoting autophagy in cumulus cells. Mogroside III, as the active ingredient of the low-polarity glycoside component (L-SGgly), L-SGgly can increase serum GLP-1 levels, improve insulin resistance, and reduce IL-6 levels, and has hypoglycemic, lipid-regulating and anti-inflammatory effects. Mogroside III can be used for the studies of type 2 diabetes mellitus (T2DM) and assisted reproductive technology.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.88%
- CAS No.: 130567-83-8
- Formule: C48H82O19
- Masse moléculaire:963.15
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Mogroside III (12.5-50 μM, 24 h) enhances oocyte in vitro maturation (IVM) and subsequent developmental potential[2].
Mogroside III (25 μM, 24 h) induces upregulation of autophagy-related genes and proteins in cumulus cells (CCs), leading to WT1 degradation and increases FSHR expression, which in turn promotes estrogen and progesterone secretion and improves oocyte quality[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Cumulus Cells
-
Concentration:25 μM
-
Incubation Time:24 h
-
Result:Increased expression of LC3, Beclin1, and ATG5 genes.
Decreased WT1 mRNA and increased FSHR mRNA.
Upregulated StAR, 3β-HSD and CYP19A1.
-
Cell Line:Cumulus Cells
-
Concentration:25 μM
-
Incubation Time:24 h
-
Result:Increased expression of LC3, Beclin1, and ATG5.
Significantly upregulated LC3B-II expression and downregulated SQSTM1 expression.
Enhances autophagic flux in cumulus cells, counteracting autophagy inhibition by 3-MA (HY-19312).
Led to accumulation of WT1 and enhanced FSHR protein levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:High-fat diet (HFD) and Streptozotocin (STZ) (HY-13753) induced T2DM model established in male SD rats (170-190 g)[1]
-
Dosage:20 mg/kg low-polar Siraitia grosvenorii glycosides, content 5.5%
-
Administration:Oral gavage (i.p.), once daily for 14 days
-
Result:Significantly reduced fasting blood sugar and improved glucose tolerance.
Significantly improved blood lipid profile.
Significantly increased serum GLP-1 levels, promoted insulin secretion, and reduced the level of pro-inflammatory factor IL-6.
Showed an upward trend on p-AMPK.
Chemical Information
-
CAS No. 130567-83-8
-
Appearance Solid
-
Masse moléculaire 963.15
-
Formule C48H82O19
-
Color White to off-white
-
SMILES
C[C@@]([C@@](CC[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]1O)O)([H])O[C@@H]1CO)C2(C)C)([H])C2=CC3)([C@@H](C[C@@]45C)O)[C@]3([H])[C@@]4(CC[C@]5([H])[C@H](C)CC[C@H](C(C)(O)C)O[C@@H]([C@@H]([C@@H](O)[C@@H]6O)O)O[C@@H]6CO[C@@H]([C@@H]([C@@H](O)[C@@H]7O)O)O[C@@H]7CO)C
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 100 mg/mL (103.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (103.83 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Tian X, et al. Mogroside III improves bovine oocyte in vitro maturation by regulating autophagy in cumulus cells. Theriogenology. 2025 Apr 15;237:1-12. [Content Brief]
[2]. Zhang Y, et al. Anti-hyperglycemic and anti-hyperlipidemic effects of a special fraction of Luohanguo extract on obese T2DM rats. J Ethnopharmacol. 2020 Jan 30;247:112273. [Content Brief]
[3]. Suzuki YA, et al. Triterpene glycosides of Siraitia grosvenori inhibit rat intestinal maltase and suppress the rise in blood glucose level after a single oral administration of maltose in rats. J Agric Food Chem. 2005 Apr 20;53(8):2941-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.0383 mL | 5.1913 mL | 10.3826 mL | 25.9565 mL |
| 5 mM | 0.2077 mL | 1.0383 mL | 2.0765 mL | 5.1913 mL | |
| 10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL | 2.5956 mL | |
| 15 mM | 0.0692 mL | 0.3461 mL | 0.6922 mL | 1.7304 mL | |
| 20 mM | 0.0519 mL | 0.2596 mL | 0.5191 mL | 1.2978 mL | |
| 25 mM | 0.0415 mL | 0.2077 mL | 0.4153 mL | 1.0383 mL | |
| 30 mM | 0.0346 mL | 0.1730 mL | 0.3461 mL | 0.8652 mL | |
| 40 mM | 0.0260 mL | 0.1298 mL | 0.2596 mL | 0.6489 mL | |
| 50 mM | 0.0208 mL | 0.1038 mL | 0.2077 mL | 0.5191 mL | |
| 60 mM | 0.0173 mL | 0.0865 mL | 0.1730 mL | 0.4326 mL | |
| 80 mM | 0.0130 mL | 0.0649 mL | 0.1298 mL | 0.3245 mL | |
| 100 mM | 0.0104 mL | 0.0519 mL | 0.1038 mL | 0.2596 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Mogroside III Related Classifications
HY-N0500 Related Classifications
Powered by Bioz